Cancer Drug Responses Greenville NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

James Ronald W Humbert, MD
(252) 816-4676
288 W Teaching Annex
Greenville, NC
Specialties
Oncology (Cancer), Pediatrics
Gender
Male
Education
Medical School: Centre Med Univ, Fac De Med, Geneve, Switzerland (Univ De Geneve)
Graduation Year: 1964

Data Provided by:
Ulf Lennart Karlsson, MD
(800) 782-8581
Greenville, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Karolinska Inst, Med Fak, Stockholm, Sweden
Graduation Year: 1968

Data Provided by:
Radhika Shah, MD
(252) 744-2560
Hem Onc Brody 3E 127 600 Moye Blvd
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Lillian P Burke, MD
(252) 744-2560
3E 127 Brody Med Sci Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Gregory A Gagnon
(252) 744-2207
600 Moye Blvd
Greenville, NC
Specialty
Hematology

Data Provided by:
Gary Richard Jones, MD
(503) 494-1543
3282 Charles Blvd
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Or Hlth Sci Univ Sch Of Med, Portland Or 97201
Graduation Year: 1980

Data Provided by:
Susan Gustke, MD
(252) 744-1000
202 W Berkshire Rd
Greenville, NC
Specialties
Internal Medicine, Hematology-Oncology
Gender
Female
Education
Medical School: Wv Univ Sch Of Med, Morgantown Wv 26506
Graduation Year: 1964
Hospital
Hospital: Pitt County Memorial Hospital, Greenville, Nc
Group Practice: Ecu Physicians Brody School Of Medicine

Data Provided by:
Howard David Homesley, MD
(252) 744-3587
Leo Jenkins Cancer Ctr
Greenville, NC
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1967

Data Provided by:
Spencer O Raa, MR
(919) 551-2554
3E-106 Brody Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Pamela A Leper, MS
(252) 758-6788
Moye Blvd 3 E 127 Brody Science Bldg
Greenville, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com